United Therapeutics Corp - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of United Therapeutics Corp Company

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

United Therapeutics Corp Info



Ticker SymbolUTHR

Company nameUnited Therapeutics Corp

IPO dateJun 17, 1999

CEODr. Martine A. Rothblatt

Number of employees1305

Security typeOrdinary Share

Fiscal year-endJun 17

Address1000 Spring St

CitySILVER SPRING

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code20910

Phone13016089292

Websitehttps://www.unither.com/

Ticker SymbolUTHR

IPO dateJun 17, 1999

CEODr. Martine A. Rothblatt

Company Executives of United Therapeutics Corp



Name

Name/Position

Position

Shareholding

Change

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

--

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

20.57K

+6.14%

Prof. Nilda Mesa, J.D.

Independent Director

5.47K

+12.08%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

Mr. Christopher Patusky, J.D.

Lead Independent Vice Chairman of the Board

2.59K

+29.50%

Ms. Jan Malcolm

Director

520.00

-57.38%

Gov. Thomas G. (Tommy) Thompson, J.D.

Independent Director

--

Mr. Christopher A. Causey

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

--

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

20.57K

+6.14%

Prof. Nilda Mesa, J.D.

Independent Director

5.47K

+12.08%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

Tyvaso DPI

315.20M

39.47%

Nebulized Tyvaso

168.30M

21.07%

Remodulin

155.70M

19.50%

Orenitram

123.90M

15.51%

Unituxin

61.40M

7.69%

Other

-25.90M

-3.24%

By RegionUSD

Name

Revenue

Proportion

United States

798.60M

100.00%

Rest of World

38.80M

4.86%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Tyvaso DPI

315.20M

39.47%

Nebulized Tyvaso

168.30M

21.07%

Remodulin

155.70M

19.50%

Orenitram

123.90M

15.51%

Unituxin

61.40M

7.69%

Other

-25.90M

-3.24%

Shareholding Stats

Updated: Fri, Aug 15

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

9.79%

BlackRock Institutional Trust Company, N.A.

9.59%

Avoro Capital Advisors LLC

5.24%

State Street Global Advisors (US)

4.79%

Renaissance Technologies LLC

4.69%

Other

65.89%

Shareholders

Proportion

The Vanguard Group, Inc.

9.79%

BlackRock Institutional Trust Company, N.A.

9.59%

Avoro Capital Advisors LLC

5.24%

State Street Global Advisors (US)

4.79%

Renaissance Technologies LLC

4.69%

Other

65.89%

Shareholder Types

Shareholders

Proportion

Investment Advisor

42.73%

Investment Advisor/Hedge Fund

37.74%

Hedge Fund

9.19%

Pension Fund

4.79%

Individual Investor

1.75%

Research Firm

1.73%

Bank and Trust

1.44%

Sovereign Wealth Fund

1.25%

Venture Capital

0.46%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

1330

44.91M

99.30%

-3.12M

2025Q2

1338

46.42M

102.62%

-2.51M

2025Q1

1369

46.67M

103.49%

-1.81M

2024Q4

1344

46.07M

102.60%

-3.00M

2024Q3

1278

45.38M

101.97%

-7.63M

2024Q2

1219

48.02M

108.26%

-2.92M

2024Q1

1151

47.12M

106.59%

-2.41M

2023Q4

1127

46.52M

99.01%

-2.26M

2023Q3

1094

46.35M

98.80%

-3.96M

2023Q2

1068

46.82M

99.96%

-3.45M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

4.43M

9.79%

-8.97K

-0.20%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.34M

9.59%

-138.61K

-3.10%

Jun 30, 2025

Avoro Capital Advisors LLC

2.37M

5.24%

-305.00K

-11.40%

Jun 30, 2025

State Street Global Advisors (US)

2.17M

4.79%

-63.20K

-2.83%

Jun 30, 2025

Renaissance Technologies LLC

2.12M

4.69%

+12.10K

+0.57%

Jun 30, 2025

Wellington Management Company, LLP

1.44M

3.19%

-583.48K

-28.79%

Jun 30, 2025

AQR Capital Management, LLC

1.27M

2.82%

+364.71K

+40.15%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.20M

2.65%

-23.63K

-1.93%

Jun 30, 2025

LSV Asset Management

864.62K

1.91%

-37.70K

-4.18%

Jun 30, 2025

Invesco Capital Management LLC

821.69K

1.82%

+445.52K

+118.44%

Jun 30, 2025

Related ETFs



Updated: Mon, Oct 6

Name

Proportion

Invesco Biotechnology & Genome ETF

4.57%

First Trust NASDAQ Pharmaceuticals ETF

3.59%

First Trust NYSE Arca Biotechnology Index Fund

3.34%

Formidable Fortress ETF

2.96%

Franklin Genomic Advancements ETF

2.73%

SPDR S&P Biotech ETF

2.57%

Inspire Faithward Mid Cap Momentum ETF

2.52%

Invesco S&P MidCap Quality ETF

2.42%

Invesco Pharmaceuticals ETF

2.3%

First Trust Health Care Alphadex Fund

2.28%

Invesco Biotechnology & Genome ETF

Proportion4.57%

First Trust NASDAQ Pharmaceuticals ETF

Proportion3.59%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.34%

Formidable Fortress ETF

Proportion2.96%

Franklin Genomic Advancements ETF

Proportion2.73%

SPDR S&P Biotech ETF

Proportion2.57%

Inspire Faithward Mid Cap Momentum ETF

Proportion2.52%

Invesco S&P MidCap Quality ETF

Proportion2.42%

Invesco Pharmaceuticals ETF

Proportion2.3%

First Trust Health Care Alphadex Fund

Proportion2.28%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data